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Abstract
Background and aims: Infliximab is currently the only biologic approved for treatment of adults
with moderate to severe, active ulcerative colitis (UC) unresponsive to conventional therapies.
It rapidly controls symptoms, induces and sustains steroid-free remission, stimulates mucosal
healing, and reduces serious complications. Although infliximab tends to be reserved fory Klinik Innere Medizin III, ABT Gastroenterologie, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
eduniwien.ac.at (W. Reinisch).
Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation.
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patients with severe disease, it may be even more beneficial for moderate disease earlier in the
disease course. Therefore, it is important to identify which patients are candidates for inflixi-
mab therapy.
Methods: A collaborative Delphi survey was used to obtain consensus on use of biologic
therapy in patients with UC from an expert panel of 12 gastroenterologists with substantial
experience using infliximab in clinical practice and clinical trials. The panel also addressed
issues that influence the use of infliximab in UC, including its potential as an alternative to
surgery.
Results: The panel agreed that: (1) it is necessary to adopt additional treatment goals be-
yond symptom control, i.e., complete mucosal healing, steroid-free remission, improved
QoL, and reduced long-term complications; (2) it may be possible to achieve these treat-
ment goals with infliximab, especially if it is used earlier in the course of UC; and (3) inflix-
imab should be offered as an alternative to surgery in patients being considered for
colectomy. The panel also agreed on factors for identifying candidates for infliximab thera-
py (e.g., persistently active UC, steroid-dependent/refractory disease, and high C-reactive
protein).
Conclusions: This consensus statement provides useful and practical information on how to
achieve evolving treatment goals with infliximab in moderate to severe UC.
© 2011 Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation.Contents
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Ulcerative colitis (UC) is a chronic inflammatory disease of the
colon with a varying course that can range from dormant to re-
fractory. Solberg et al. posit 4 patterns: initial high activity to
remission or mild severity; initial low activity to increased se-
verity; continuous symptoms; and intermittent symptoms.1
UC may become milder with increasing age, but relapse is
still common in patients with mild-to-moderate disease.1 UC
is conventionally treated with symptom-focused step-up
therapy comprising aminosalicylates, corticosteroids, and
immunomodulators (e.g., 6-mercaptopurine [6-MP] or azathi-
oprine [AZA]). While a 1994 assessment showed that with thisapproach UC remained active in up to 50% of patients after a
few years, and one-fifth of these patients required colectomy
within 10 years,2 a more recent assessment is less gloomy:
only one-tenth of conventionally treated patients required
colectomywithin 10 years.1 The course of UC in these patients
is unclear, but corticosteroid use has been associated with
poor prognosis in up to 50% of patients.3 Furthermore, al-
though AZA is regularly used to treat patients with UC not
responding to aminosalicylates and corticosteroids, evidence
supporting its use is limited. One meta-analysis suggested
that the probability of treatment success with AZA is similar
to, or at best marginally more beneficial than, aminosalicy-
lates or placebo.4
Table 1 Qualifications and responsibilities of the Delphi
participants.
Steering committee
Qualifications
• Possess extensive experience using biologic therapies to
treat patients with moderate to severe UC
• Involved in numerous clinical trials evaluating biologic
therapies in UC
Responsibilities
• Develop survey outline topics
• Contribute to the survey design/methodology
• Review survey data before sending to the expert panel
• Present data to the expert panel at an on-site meeting
Expert panel
Qualifications
• Possess substantial experience using biologic therapies
to treat patients with UC
• Involved in some clinical trials evaluating biologic
therapies in UC
Responsibilities
• Participate in 2 rounds (rounds 1 and 2) of an anonymous
questionnaire
• Attend a group discussion meeting (round 3) of survey
results to establish consensus, where possible
• Develop additional/revised questions at the meeting
and respond to the revised questions (round 4)
250 W. Reinisch et al.It is now recognized that treatment goals must go be-
yond controlling symptoms, to influencing the underlying
cause of UC via fast, sustained control of inflammation.
UC treatment should aim to rapidly induce steroid-free re-
mission, achieve complete mucosal healing (an objective
indicator of inflammation control and bowel normalisa-
tion), avoid serious complications (e.g., hospitalisations
and surgeries), minimize side effects, and improve patient
quality of life (QoL).5 Achievement of these challenging
treatment goals is possible in more patients since the intro-
duction of biologic therapies.
Currently, infliximab is the only biologic therapy approved
for treatment of UC. It was approved in 2006 by the European
Commission for the treatment of moderate to severe, active
UC in patients with an inadequate response to conventional
therapy, including corticosteroids and 6-MP or AZA, or who
are intolerant or have medical contraindications to such ther-
apies.6 In addition, the European Crohn's and Colitis Organisa-
tion (ECCO) UCmanagement guidelines recommend infliximab
in steroid-refractory and thiopurine-refractory UC.7 Inflixi-
mab tends to be used as a third-line therapy in patients with
moderate to severe UC or as a rescue therapy. However, ex-
perts have proposed that earlier use during less severe disease
states (i.e., moderate UC) could benefit many patients.5 Fur-
thermore, infliximab can potentially attain the new treatment
goals beyond symptom control in these patients.8–10 Interest-
ingly, combination therapy with infliximab and AZA may be
the new best approach, according to results from a double-
blind, randomized, controlled trial (RCT) presented at the
ECCO conference,11 but not yet published in full.
The objective of the present survey was to assess current
expert practices and establish pragmatic principles for
candidate selection and timing of infliximab therapy. It is
hoped that the results of this cooperative effort will assist
clinical practice.
2. Materials and methods
2.1. Survey participants
A steering committee comprising 3 gastroenterologists (WR,
GvA, and JP) with extensive experience using biologic thera-
py to treat UC, both in clinical trials and the clinical setting,
helmed the Delphi process. Committee members developed
topics for the survey and helped with design and methodolo-
gy (Table 1), but did not participate in the survey. When
complete, the survey was reviewed by the steering commit-
tee and then independently tested to ensure that the ques-
tions were understandable, with no ambiguities.
Twelve gastroenterologists from Europe, Canada, and
Australia agreed to form an expert panel and to participate
in the survey under the supervision of the steering group.
The members of the expert panel were selected based on
their substantial level of expertise in using biologic therapy
in the treatment of UC in both clinical practice and clinical
studies (Table 1).
2.2. Delphi methodology
The Delphi methodology, developed by Linstone and Turoff,
provides an evidence-based method for structured groupcommunication that allows a group of individuals to effec-
tively explore and solve complex problems.12 A major
strength of this approach is that it can be used to look at a
specific problem/argument from all angles, determine the
pros and cons of different approaches to the problem, and
help clarify the impact and acceptability of specific ideas
and opinions.12,13 The Delphi methodology modifies individ-
ual viewpoints and leads to a merging of opinion within a
group.
The Delphi methodology has been modified to allow es-
tablishment of a consensus. Known as the “collaborative
Delphi,” this modification uses a combination of surveys
and meetings. The approach involves a steering group
that identifies the issues surrounding a complex problem,
and a survey questionnaire to which an expert panel
anonymously responds. By undergoing repeated rounds
of the survey and subsequent analysis/modification
of the questions, it is possible to reach a group
consensus.
In this study, consensus was reached using the collabora-
tive Delphi method, which was executed in 2 rounds of an
anonymous survey (rounds 1 and 2) followed by a meeting
(round 3). During the meeting, the anonymity of the expert
panel members was relinquished. Individual survey re-
sponses were not disclosed, however, to maintain objectivi-
ty. Consensus was reached on many topics at the end of the
meeting, and additional questions were developed which
were then sent to the expert panel to be answered anony-
mously (round 4).
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This Delphi survey focused on 5 topics relating to the use of
biologic therapy in the treatment of UC. Specifically, the
questionnaire addressed issues that:1. influence the decision to use a biologic as treatment for UC.
2. influence the decision to use infliximab as treatment for UC.
3. relate to the importance of proper timing of infliximab
treatment.
4. relate to surgery for UC.
5. influence the decision to use infliximab as an alternative to
surgery.
Questions were formulated to measure areas of agree-
ment, relevance, importance, and likelihood of action. A
Likert scale of 1 to 9 was used, where a score of 1, 2, 3 or
4 indicated degrees of disagreement with the statement or
question, and a score of 6, 7, 8 or 9 indicated increasing de-
grees of agreement. A score of 5 was considered neutral.
The expert panel completed the internet-based question-
naire during rounds 1 and 2 of the Delphi process. A numeri-
cal identification system ensured that the participants
remained anonymous.
2.4. Data analysis
After completion of round 1, the responses were collected
and analyzed as a group. Median scores were calculated to
obtain an accurate measure of main tendencies and discount
any extreme views. During round 2, these median scores
were made known to the expert panel. After this round of
the Delphi process and before the round 3 meeting occurred,
the variability of the responses was calculated using the
interquartile range (IQR; a measure of the distance between
the 75th and 25th percentiles that reflects the middle 50% of
responses). IQR gives a stable measure of the response range
that is not swayed by outliers or extreme responses.1 2 3 4 5 6
Strongly 
Disagree
Median
Minimum 
value
Figure 1 Description of boxplot.Sample distribution of scores sh
kers”), and extremes. IQR is a measure of distance between 75th
gives a stable measure of response range that is not swayed by outlie
dian≥7 plus IQR≥7 (negative consensus, median≤3 and IQR≤3). B
and maximum scores may be considered outliers.The results of the survey were presented to the expert
panel by the steering committee during a meeting (round
3). Key issues surrounding the use of biologic therapy in UC
were discussed to establish importance, relevance to patient
treatment, and likelihood of specific actions (e.g., use of cy-
closporine over infliximab). To further clarify the degree of
agreement with a question or statement, the median Likert
scoring scale was adjusted. Statements or questions were
re-categorised as “highly irrelevant, strongly disagree, or
highly unlikely” (median score 1–3); “somewhat relevant
or irrelevant, somewhat agree or disagree, or somewhat
likely or unlikely” (median score 4–6); or “highly relevant,
strongly agree, or highly likely” (median score 7–9). Positive
consensus was defined as the median≥7 plus the lower
quartile≥7 (negative consensus, median≤3 and upper quar-
tile≤3). Scores can be illustrated with “boxplots” (Fig. 1).
Each consensus was based on expert opinion and clinical
experience.
3. Results
Delphi participants based their responses on their familiarity
with and knowledge about infliximab, because at the time of
this survey it was the only biologic approved for the treat-
ment of UC.
3.1. Factors influencing the decision to use biologic
therapy
The expert panel agreed that the efficacy of biologic thera-
py demonstrated in similar clinical conditions (median 7 [IQR
7–8]) and its ability of to change the disease course (median
8 [IQR 7–8]) play a large role in their decision to recommend
biologic therapy to patients with UC. Panelists also consid-
ered these efficacy factors highly relevant: speed of clinical
improvement (median 7 [IQR 7–8]); ability to achieve muco-
sal healing (median 7.5 [IQR 7–8]) and better QoL (median
8 [IQR 7–8]); and avoidance of colectomy (median 8 [IQR
8.0–8.25]). When focusing on patient characteristics and7 8 9
Strongly 
Agree
No Consensus
No Consensus
Consensus 
Regarding 
Agreement
Consensus 
Regarding 
Disagreement
Maximum 
value
owing median, interquartile range (IQR, represented by “whis-
and 25th percentiles that reflects middle 50% of responses. It
rs or extreme responses. Positive consensus was defined as me-
ox at far left indicates all scores were 1 to 2 inclusive. Minimum
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important when considering biologic therapy in patients
with UC:Table 3 Consensus: patient factors highly relevant when
initiating infliximab.
• Previous treatment failures:
Previous treatment failures
• Steroids
(median 8 [IQR 7–8])
• 6-MP
(median 8 [IQR 7.5–8.0])
Severity of current
symptoms (median 8
[IQR 7–8])
Extraintestinal
manifestations
(median 7 [IQR 7.0–7.5])
Active infection
(median 9 [IQR 8–9])
Poor QoL (median 8
[IQR 8–8])
Previous adverse events
to 6-MP (median 7
[IQR 7–8])
Previous history of TB
exposure (median 9
[IQR 7.5–9.0])
Risk of latent TB reactivation
(median 8
[IQR 7–9])
Patient willingness to try a
biologic (median 8 [IQR 7–8])
and comply with treatment
(median 8 [IQR 8–8])
Patient desire to avoid
surgery (median 8 [IQR 8–8]).3.2. Factors influencing the decision to
use infliximab
3.2.1. Treatment goals
The panel recognized the importance of going beyond
symptom control to achieve additional treatment objectives
(Table 2). There was consensus that treatment with infliximab
may: improve symptoms/reduce number of flares (median
8 [IQR 7–8]), heal mucosal lesions (median 8 [IQR 7–8]), redu-
ce hospitalisations and surgeries (median 7.5 and 8, respec-
tively [IQR 7.75–8.0]), reduce dependence on steroids
(median 8 [IQR 7–8]), and improve patient QoL (median
8 [IQR 7.75–8.0]). All of these goals, as well as restoring pa-
tient productivity (median 7 [IQR 7–8]) and achieving
steroid-free clinical remission (median 8.0 [IQR 7.75–9.0])
were determined to be highly relevant factors in the decision
to select infliximab for UC patients.Table 2 Consensus: treatment goals highly relevant in the
decision to use infliximab in patients with ulcerative colitis.
• Achieve fast clinical improvement (median 8
[IQR 7.75–8.0])
• Maintain symptom control (median 8 [IQR 7.75–8.25])
• Achieve mucosal healing (median 7 [IQR 7–8])
Maintain normal gut function
Maximize bowel preservation
Change natural course of disease
• Improve quality of life (median 8 [IQR 7–8])
Improve feelings of social acceptability
Reduce physical impact of disease
• Avoid adverse effects of steroids (median 8 [IQR 7–8])
• Avoid surgery (median 8 [IQR 8–8])3.2.2. Patient selection
Panelists agreed that they would recommend infliximab
to candidates ≥16 years old and up to 70 years old (median
8 [IQR 7–9]). However, no consensus was reached on recom-
mending infliximab to patients older than 70 (median 6 [IQR
5.0–6.5]), and the most relevant factor to this decision in
this age group was safety (median 8 [IQR 8–9]). Malignancy
(median 6 [IQR 4.5–7.5]) and surgical risks (median 7 [IQR
5.5–7.5]) were deemed by some to be relevant to the deci-
sion. Experts also were asked about the likelihood they
would recommend infliximab to a female candidate with
established UC who was pregnant or wished to become preg-
nant. Consensus was lacking regarding existing pregnancy
(median 7 [IQR 6–7]), although the majority were highly
likely to recommend infliximab to those planning pregnancy
(median 7 [IQR 7–8]). Several other patient- and disease-
specific factors also were considered highly influential in
the decision to use infliximab (Table 3). Panelists agreed
that patients with a previous history of TB exposure (median
9.0 [IQR 7.5–9.0]) or risk of latent TB reactivation (median
8 [IQR 7–9]) have relative contraindications to treatment
with infliximab. Panelists agreed with product labeling that
those with active infection (median 9 [IQR 8–9]; positive
consensus) or congestive heart failure (median 2 [IQR 1–2];
negative consensus) are not candidates for infliximab.3.2.3. Disease status
Of assessment measures, results of the Physician Global
Assessment were considered highly relevant (median 8 [IQR
7–8]) in the decision to treat UC with infliximab. No consen-
sus could be reached on the relevance of multiple other clin-
ical factors, including endoscopic involvement, histology
grade, laboratory results (e.g., elevated CRP and ESR), and
previous medications. The panel agreed that patients
with persistently active UC and steroid dependence or resis-
tance must be identified correctly to ensure appropriateFailed and/or did not tolerate steroids
(median 8 [IQR 7.5–8.5])
Failed and/or did not tolerate azathioprine and/or 6-MP
(median 8 [IQR 8–9])
• Steroid dependence (median 8 [IQR 8.0–8.25])
• Steroid intolerance or resistance (median 8
[IQR 7.5–8.5])
• Severity of current symptoms a (median 8 [IQR 7–8])
• Persistently active disease+laboratory results
(median 8 [IQR 7–8])
• Frequent flares (median 8.5 [IQR 8.0–9.0])
• Severe flare at time of office visit (median 7 [IQR 7–8])
• Persistence of mucosal lesions (median 7 [IQR 7–8])
• Presence of extraintestinal manifestations (median 7.0
[IQR 7.0–7.5])
• Nocturnal stooling (median 7.0 [IQR 7.0–7.25])
a Nocturnal stooling, urgency, blood in stool, anemia, inconti-
nence, tenesmus, pain, and malnutrition.
253Treatment consensus: infliximab in ulcerative colitistreatment—accurate definitions are essential. There was ac-
cord that the ECCO guidelines provide useful definitions of
these disease states, and the expert panel expanded on
them (Table 4).
3.2.4. Patient quality of life
The expert panel agreed that improvement in patient QoL
is achievable with infliximab in patients with UC (median 8.0
[IQR 7.75–8.0]). Consensus also was reached that restoring
patient QoL is highly relevant in the decision to select inflix-
imab (median 8 [IQR 7–8]).
3.3. Factors related to timing of infliximab therapy
Some of the expert panel agreed that initiating infliximab
when disease is not yet severe, earlier in the course of UC,
increases the likelihood of achieving treatment goals, i.e.,Table 4 Definitions from ECCO guidelines and definitions produc
Definitions from ECCO guidelines7
Persistent active UC Persistent symptoms of active UC with
a period of remission, i.e., when the
of relapse is not infrequent but rathe
continuous
Steroid-dependent UC Patients who are either unable to red
steroids below the equivalent of pred
10 mg/day within 3 months of starting
without recurrent active disease, or w
a relapse within 3 months of stopping
Steroid-refractory UC UC patients who have active disease d
prednisolone up to 0.75 mg/kg/day ov
period of 4 weeks
Remission Complete resolution of symptoms and
endoscopic mucosal healing: stool fre
≤3/day with no bleeding, and normal
quiescent mucosa at endoscopy
ECCO = European Crohn's and Colitis Organisation, CRP = C-reactive prsymptom relief, reduced flares, mucosal healing, fewer
complications (hospitalisation and surgeries), and improved
QoL, but there was no consensus. Consensus was reached
only on the statement that using infliximab earlier in the
course of disease increases the likelihood of reducing patient
dependence on steroids (median 8 [IQR 7–8]).3.4. Issues regarding surgery for ulcerative colitis
Most of the panel agreed that patient fear of the surgical
procedure and patient age N70 were highly relevant in the
decision to use infliximab. Consensus was reached that pa-
tient fears about the consequences of surgery (median 7
[IQR 7–8]) and possible surgical complications (median 7
[IQR 7.0–7.5]), and patient desire to avoid surgery (median
7 [IQR 7–8]) were highly relevant to the decision. Consensused by the expert panel.
Definitions from expert panel consensus
out
pattern
r
Symptoms of active UC for 6–9 months out
of a 12-month period:
• N4 bowel movements per day independent
of other symptoms
• Elevated inflammatory biomarkers
(e.g., CRP)
• Blood in stools
• Mucosal lesions
• Persistence of loose stools with blood and
urgency
• Steroid-dependent or immunosuppressive-
refractory disease
• Persistence of any symptom of disease
activity
• Low QoL
• Weight loss, anemia, malnutrition and
fatigue
uce
nisolone
steroids,
ho have
steroids
None
espite
er a
• Failure to respond to prednisone
40–60 mg or equivalent in 2 to 4 weeks
• Failure to achieve remission with
prednisone 40–60 mg or equivalent in
4 weeks
• Failure to respond to up to 1 mg/kg body
weight of prednisone after 4 weeks
quency
or
• Normalisation of bowel function and
absence of blood
• Cessation of UC symptoms, complete
endoscopic and histologic healing
• Normal or improved endoscopy, normal
fecal calprotectin, disappearance of
symptoms that required treatment
• Prolonged absence of symptoms off steroids
otein, and QoL = quality of life.
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geries (median 8 [IQR 7–8]).3.5. Infliximab as an alternative to surgery
The expert panel stated that they routinely consult with sur-
geons prior to making treatment decisions in patients suit-
able for elective colectomy or infliximab therapy.
Consensus was reached that infliximab can be used as an
alternative to surgery in many patients with acute, severe
UC at imminent risk of colectomy (Fig. 2). The expert panel
agreed that many patients with moderate to severe, persis-
tently active UC considered at risk of colectomy, or those
with severe UC failing intravenous (IV) steroids are candi-
dates for infliximab. The expert panel would use infliximab
rather than cyclosporin in patients with severe active or
chronic acute UC as an alternative to surgery, because inflix-
imab was considered safer and easier to administer. There
was consensus that treating acute UC patients with inflixi-
mab prolongs the time to colectomy (median 8 [IQR 7–8]).
The panel reached consensus that mucosal healing can be
sustained with infliximab over time (median 8 [IQR 7–8]),
and that rapid, sustained mucosal healing leads to clinical re-
mission (median 8 [IQR 7–8]), reduced colectomy risk (median
8 [IQR 7.5–8.25]), better long-term outcomes (median 8 [IQR
8–9]), and improved patient QoL (median 7.5 [IQR 7.0–8.0]).Mucosal healing can be sustained with
infliximab over time.
Persistence of mucosal lesions is a factor in my
decision to use in fliximab, once clinical parameters
warrant biologic therapy
How relevant is achievement of mucosal
healing by patients receiving infliximab in
your decision to use infliximab?
1 2 3
A
B
4
1 2 3 4
Treatment with infliximab leads to mucosal healing. 
Strongly disagree
Highly irrelevant
Strongly disagree
Infliximab prolongs the time to colect
in patients with acute 
Infliximab reduces the likelihood of colect
in patients with persistent, active 
Achieving mucosal healing in UC
reduces the risk of colectomy.  
Patients with persistent, moderate to severe, ac
are at risk of colectomy are candidates fo
Figure 2 The decision to use biologic therapy/infliximab⁎ and issu
sensus included the benefits of biologic therapy to mucosal healing a
the time of this survey, infliximab was the only biologic approved fo4. Discussion
The results of this Delphi survey underscore the potential of
biologic therapy to change the disease course in UC. The ex-
pert panelists identified speed of clinical improvement, abil-
ity to achieve mucosal healing, better QoL, and avoidance of
colectomy as critical factors in the decision to recommend
biologic therapy to their patients. A variety of other factors
also were deemed highly relevant, including previous treat-
ment failures and presence of extraintestinal manifesta-
tions. Although the survey included questions about cost
and reimbursement, consensus could not be reached due to
regional reimbursement rules. Consensus was achieved in
many other areas, however (Table 5).
Accurate identification of candidates for biologic therapy
is essential—the panel achieved consensus on this point.
Therefore, the definitions of “persistently active,” “steroid
dependent,” and “steroid resistant” UC and of “remission”
are important to ensure appropriate treatment. There was
accord among panelists that the ECCO guidelines provide
useful definitions, and the panelists expanded them with
specific criteria.
The panelists were in consensus that their decisions to
use infliximab were based on clinical trial data (median
8 [IQR 7–8]) showing significant clinical response within
8 weeks, ability to achieve clinical remission and discontinue
steroids, and stimulation of mucosal healing, as well as on 
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Table 5 Summary: consensus areas reached during the
Delphi process.
Factors influencing the decision to use biologic therapy
Treatment goals:
• Rapid steroid-free remission (median 8 [IQR 7.75–9.0])
• Complete mucosal healing (median 8 [IQR 7–8])
• Reduction in hospitalisations and surgeries
(median 8 [7.75–8.0])
• Improved patient QoL (median 8 [IQR 7–8])
Factors influencing the decision to use infliximab
Candidate characteristics:
• Persistently active, moderate to severe UC
(median 8 [IQR 7–9])
• Acute severe UC (median 8 [IQR 7–9])
• Steroid-dependent UC (median 8 [IQR 8.0–8.25])
• Steroid-refractory UC (median 8 [IQR 8–9])
Quality of life issues:
• Symptoms of active UC, i.e., nocturnal stooling,
malnutrition, urgency, blood in stool, anemia,
incontinence (medians 7–8 [IQRs 7–8.25])
• Physical impact of disease on patient (median 8 [IQR 7–8])
• Inability to perform job function (median 8 [IQR 7–8])
• Improvement in QoL desired in majority of patients
(median 8 [IQR 7–8])
• Cyclosporine side effects—use infliximab in severe acute
(median 8 [IQR 6.5–9.0]) and in chronic, active UC
(median 8 [IQR 8–9])
Alternative to surgery a:
• Acute severe UC (median 8 [IQR 7–9])
• Moderate to severe, persistently active UC at risk for
colectomy (median 8 [IQR 7–9])
• Severe UC failing IV steroids (median 7 [IQR 7–7])
• Infliximab prolongs the time to colectomy (median 8
[IQR 7–8])
• Infliximab reduces the likelihood of colectomy (median 7
[IQR 7–8])
• Mucosal healing reduces risk of colectomy (median 8
[IQR 7.5–8.5])
• Infliximab can potentially achieve mucosal healing
(median 7 [IQR 7–8])
CRP = C-reactive protein, ESR = erythrocyte sedimentation rate,
and QoL = quality of life
a Infliximab may be tried before surgery in some patients.
255Treatment consensus: infliximab in ulcerative colitislong-term safety data (median 7.5 [IQR 7–8]) from inflam-
matory bowel disease (IBD) cohorts and registries. (For ex-
ample, see8,9,14,15.) There was positive consensus that in
some patients, infliximab has the potential to: improve
symptoms, reduce flares, stimulate mucosal healing, reduce
hospitalizations and surgeries, reduce dependence on
steroids, improve QoL, restore productivity, and achieve
steroid-free clinical remission.
Panelists strongly agreed that restoring QoL is an impor-
tant treatment goal. The symptoms of active UC (e.g. noc-
turnal diarrhea, urgency, incontinence, tenesmus and pain)
can have a significantly negative effect. The impact must
be reduced so that patients can perform at work and enjoy
leisure activities, both of which encourage feelings of socialacceptability. Also, patients' stress/anxiety about disease
symptoms and long-term effects, and any fears regarding
surgery must be addressed. Importantly, perceptions of
QoL vary, so interpretations of improvement should be
assessed on a patient-by-patient basis. There was strong
consensus among panelists that the goal of restoring QoL
was highly relevant in the decision to recommend infliximab.
Panelists strongly agreed that using infliximab earlier in
the course of disease may improve the likelihood of achieving
treatment goals. Currently, infliximab tends to be used in pa-
tients with more severe disease. Although there is strong ev-
idence in Crohn's disease (CD) showing benefits of initiating
infliximab early,16 the data in UC is scant. Some experts rec-
ommend considering use of infliximab in patients with mod-
erately severe UC who are steroid-dependent or steroid-
refractory.5 Our expert panel reached positive consensus in
agreeing with this recommendation (median 8 [IQRs 7–8
and 8–9, respectively]). Interestingly, data for use of inflixi-
mab in patients with moderate disease is building. In a cohort
of 115 patients receiving infliximab, those with moderately
severe compared with severe UC had a higher rate of clinical
response (70% vs. 41%, P=0.004) and clinical remission (41%
vs. 17%, P=0.015).17 A posthoc analysis of data from the Ac-
tive Controlled Ulcerative Colitis Trial (ACT) 1 and 28 showed
that infliximab patients who had mucosal healing at week 8
(Mayo endoscopic subscore classification 0 — normal or 1 —
mild) were less likely to progress to colectomy at week 54
(P=0.0004).18 Note that 63.8% of these patients (309/484)
had moderate disease at baseline.19
UC SUCCESS, a 16-week trial in biologic-naïve patients
with moderately severe UC, is now complete. Patients
were failing corticosteroids and either naïve to AZA or had
stopped AZA ≥3 months before entry. Combination therapy
with infliximab and AZA was found to be superior to both
AZA (Pb0.05) and IFX (nominal Pb0.05) monotherapy in in-
ducing steroid-free remission in patients with moderately
severe UC.11 Also, patients treated with an IFX-based strat-
egy were more likely to achieve response and mucosal heal-
ing than those treated with AZA monotherapy. A full report
of this trial has not yet been published, but the data have
been orally presented at ECCO 2011.11 The results must be
extended and investigated further.
Some patients have a more progressive form of UC that is
associated with poor outcomes (e.g., increased hospitaliza-
tions and colectomy and mortality rates). Predictive factors
of poor prognosis in UC have been identified. A subanalysis
of ACT 1 and 2 revealed that steroid dependency, high
(≥2 mg/dL) baseline C-reactive protein (CRP), high disease
severity (Mayo 10–12), and moderate to severe, active
UC of short disease duration (≤3 years) were significantly
associated with increased risk of colectomy.10 In a retro-
spective single-center analysis, independent predictors of
colectomy included absence of short-term clinical re-
sponse, baseline CRP≥5 mg/dl, and previous intravenous
treatment with cyclosporine and/or corticosteroids.9 A
multicenter study had similar results, with the addition of
a diagnosis of acute severe colitis.20 In routine clinical prac-
tice, physicians have to decide when to initiate infliximab
therapy and for which patients. Currently, there are limited
published data from large RCTs on selecting patients with
these identifying factors for treatment with infliximab be-
fore rapid progression.
256 W. Reinisch et al.Patients with moderate to severe, active UC may require
surgery for refractoriness to conventional treatments or for
complications of their disease. The ACT trials showed that
infliximab significantly reduces the risk of UC-related hospi-
talisations and surgeries.10 Importantly, infliximab is an
effective rescue therapy in patients with severe or moder-
ately severe UC not responding to conventional therapy.21,22
Cyclosporin also is effective initially for rescue therapy, but
many patients will require colectomy in the long term.23 Pa-
tients with 6-MP/AZA failure who subsequently receive cy-
closporin are especially at risk of colectomy.23 Moreover,
the necessity of frequent monitoring and the toxicity risk as-
sociated with cyclosporin tend to make infliximab more
appealing to gastroenterologists. An RCT comparing inflixi-
mab and cyclosporine has not been published, but prelimi-
nary data suggest equal efficacy in 111 patients failing IV
steroids.24
In a recent retrospective survey of 86 patients with
steroid-refractory UC or indeterminate colitis, 65 had failed
to respond to cyclosporine and were treated with infliximab
as the second-line rescue therapy (CYS-IFX), and 21 had
failed to respond to infliximab and were treated with cyclo-
sporine second-line (IFX-CYS).25 Median follow-up was 22.6
±7.0 months. At month 3, 25% of patients (16/65) in the
CYS-IFX subgroup and 14% of patients (3/21) in the IFX-CYS
subgroup were in remission without steroids. (Three addi-
tional were in remission but with steroids.) Among the 65 pa-
tients treated with CYS-IFX, 35 (54%) were operated. Among
the 21 patients treated with IFX-CYS, 14 (67%) were operat-
ed. The colectomy rate was similar whatever agent was used
as the first salvage therapy. No difference in Kaplan–Meier
colectomy-free survival curves was observed between the
groups. In this study, a significant number of patients
avoided colectomy by switching these agents for second-
line therapy.25 IFX-CYS rescue therapy is administered to pa-
tients with severely acute UC in hospital only.
This discussion would not be complete without addressing
areas of non-consensus in our Delphi process. These areas,
which arose due to lack of data, included prescribing inflix-
imab to pregnant patients or to those N70 years old. Age
N70 was considered highly relevant in the decision to use
infliximab if the other option was surgery. A recent Austrian
(non-Delphi) consensus on safety issues related to use of
infliximab in IBD noted, as does infliximab product labeling,6
that no studies have focused on the safety of infliximab in
the elderly.26 Sparse data constrained these experts, who is-
sued 1 statement pertaining to this demographic: “Close
monitoring for infectious complications is mandatory in IBD
patients with higher age.”
A subsequent subanalysis demonstrated harmful effects
in the elderly.27 Comparison between a prospectively
recruited study group of 95 patients N65 years old treated
with infliximab or adalimumab and retrospective matched
controls (190 patients ≤65 years old treated with both bio-
logics plus 190 patients N65 years old treated with other
drugs) showed that those N65 years old and treated with
TNF inhibitors (TNFi) had a high rate of infections and mor-
tality compared with younger patients, or same-age patients
who did not receive TNFi. However, these results must be
viewed with caution due to several study limitations (e.g.,
retrospective controls, uncertainty about whether disease
severity was greater in biologically treated control patients,innate higher risk of infection in elderly due to comorbid-
ities, mortality already higher in elderly with IBD).27
Therefore the message reiterates product labeling in recom-
mending that particular attention be paid to treatment of
the elderly.
Similarly, our Austrian colleagues could make no recom-
mendation to continue or initiate infliximab during pregnan-
cy.26 The product label recommends against it.6 However,
ECCO has rated infliximab as “probably safe” during pregnan-
cy and lactation, with the following official statements28:
• Use of 5-ASA derivatives, corticosteroids and biologicals is
not significantly associated with malformations or adverse
outcomes in pregnant IBD patients and their offspring.
• All anti-TNFs are likely to be excreted in the breast milk in
very small amounts. However, no adverse effects have
been reported in the small number of infants breastfed by
mothers on this therapy.
• Infliximab is of low risk in pregnancy, both for the early and
late outcomes, and does not seem to be a teratogenic.
The World Congress of Gastroenterology has taken a near-
ly identical position.29 However available data are mostly
observational only.30–33 Moreover, outcomes of 130 preg-
nancies in the U.K. British Society for Rheumatology Bio-
logics Register (BSRBR) led researchers to conclude that no
firm conclusions can be drawn about use of TNFi in pregnan-
cy, and such treatment during conception may even be asso-
ciated with increased risk of spontaneous abortion.34 Since
our Delphi was conducted, conflicting evidence has accumu-
lated for both a lack of infliximab-associated adverse preg-
nancy outcomes35,36 and cause for concern32,37—sometimes
in the same article.33 There is general agreement, however,
that infliximab should be stopped during the last trimester
of pregnancy.
The relevance of disease status in choosing to use inflixi-
mab also was an area of non-consensus in our Delphi. This re-
sult is perhaps unsurprising, since with multiple disease
distribution patterns, activity levels, and possible courses,
UC presents a minimum of 48 different scenarios for consider-
ation—not including critical factors such as age, concomitant
illnesses, and previous medications and surgeries.38 Addition-
ally, while the ECCO guidelines7 provide useful definitions of
disease states, they do not specify the significance of multiple
clinical factors. To our knowledge, this has not yet been done
in UC. Furthermore, although efforts in CD to identify patients
at risk and predict outcomes of various treatments have pro-
vided valuable information, comparatively little is known in
UC.38,39 A thorough examination of these factors is beyond
the scope of this article. But clearly, more research is needed
upon which expert panels such as ours may base their opinions
and thereby reach consensus.
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